ES2107192T3 - Compuestos de alquilamino etinil alanina amino diol morfolino/tiomorfolino-terminados utiles como inhibidores de renina. - Google Patents

Compuestos de alquilamino etinil alanina amino diol morfolino/tiomorfolino-terminados utiles como inhibidores de renina.

Info

Publication number
ES2107192T3
ES2107192T3 ES94908055T ES94908055T ES2107192T3 ES 2107192 T3 ES2107192 T3 ES 2107192T3 ES 94908055 T ES94908055 T ES 94908055T ES 94908055 T ES94908055 T ES 94908055T ES 2107192 T3 ES2107192 T3 ES 2107192T3
Authority
ES
Spain
Prior art keywords
thyomorfoline
ethinyl
alkylamine
morpholine
amino diol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94908055T
Other languages
English (en)
Inventor
Gunnar J Hanson
Robert E Manning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Application granted granted Critical
Publication of ES2107192T3 publication Critical patent/ES2107192T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LOS COMPUESTOS CARACTERIZADOS GENERALMENTE COMO DERIVADOS DE AMINO DIOL DE ALQUILAMINO-ETINIL-ALANINA TERMINADOS EN MORFOLINO/TIOMORFOLINO SON UTILES COMO INHIBIDORES DE LA RENINA PARA EL TRATAMIENTO DE LA HIPERTENSION. COMPUESTOS DE PARTICULAR INTERES SON AQUELLOS DE LA FORMULA (I) EN LA QUE A SE SELECCIONA ENTRE CO Y SO2; X SE SELECCIONA ENTRE UN ATOMO DE OXIGENO Y METILENO; B SE SELECCIONA ENTRE UN GRUPO DE MORFOLINO, UN GRUPO DE TIOMORFOLINO, GRUPOS HOMOLOGOS HETEROCICLICOS DE CUATRO, CINCO Y SIETE MIEMBROS DE MORFOLINO Y GRUPOS DE TIOMORFOLINO, Y DERIVADOS PUENTEADOS CON OXO-, ALQUILOGRUPOS; R1 SE SELECCIONA ENTRE HIBRIDO, METILO, ETILO, ISOPROPILO Y N-PROPILO; R2 ES FENILMETILO; CADA R3 Y R5 ES HIBRIDO; R4 SE SELECCIONA ENTRE , EN DONDE V SE SELECCIONA ENTRE HIBRIDO Y METILO; R6 ES CICLOHEXILMETILO, R7 SE SELECCIONA ENTRE ISOBUTILO, CICLOPROPILO Y CICLOPROPILMETILO; Q ES UN NUMERO SELECCIONADO ENTRE 0 Y 3; Y N ES UN NUMERO SELECCIONADO ENTRE 0 Y 3; TAMBIEN SE PRESENTAN LAS SALES FARMACOLOGICAMENTE ACEPTABLES DE LOS COMPUESTOS.
ES94908055T 1992-08-14 1993-08-13 Compuestos de alquilamino etinil alanina amino diol morfolino/tiomorfolino-terminados utiles como inhibidores de renina. Expired - Lifetime ES2107192T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/930,069 US5422349A (en) 1992-08-14 1992-08-14 Morpholino-oxazinyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension

Publications (1)

Publication Number Publication Date
ES2107192T3 true ES2107192T3 (es) 1997-11-16

Family

ID=25458882

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94908055T Expired - Lifetime ES2107192T3 (es) 1992-08-14 1993-08-13 Compuestos de alquilamino etinil alanina amino diol morfolino/tiomorfolino-terminados utiles como inhibidores de renina.

Country Status (11)

Country Link
US (15) US5422349A (es)
EP (1) EP0655062B1 (es)
JP (1) JPH08500119A (es)
AT (1) ATE159014T1 (es)
AU (1) AU687753B2 (es)
CA (1) CA2136842A1 (es)
DE (1) DE69314497T2 (es)
DK (1) DK0655062T3 (es)
ES (1) ES2107192T3 (es)
GR (1) GR3025521T3 (es)
WO (1) WO1994004518A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8800986A1 (es) * 1985-07-27 1987-12-01 Pfizer Un procedimiento para la produccion de un nuevo derivado de avermectina
US5508466A (en) * 1994-04-13 1996-04-16 G.D. Searle & Co. Synthesis of N-protected-α-substituted-glycine racemic esters by zinc-mediated addition of organic halide to glycine cation equivalent
EP0702004A2 (de) * 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
US5725460A (en) * 1996-07-15 1998-03-10 Marsh; John P. Adjustable weight lifter's bench
US5912006A (en) * 1996-08-28 1999-06-15 Eboc, Inc. Compositions and methods for alleviating discomforting menstrual pain
FR2774752B1 (fr) * 1998-02-06 2000-06-16 Air Liquide Installation de distillation d'air et boite froide correspondante
US7332550B2 (en) * 2000-10-06 2008-02-19 Carnegie Mellon University Stabilization of transition metal complexes for catalysis in diverse environments
MXPA04004713A (es) * 2001-11-19 2005-08-16 Pharmacia & Up John Company Ll Aminoides utiles en el tratamiento de la enfermedad de alzheimer.
US6875438B2 (en) * 2002-04-27 2005-04-05 Aventis Pharma Deutschland Gmbh Preparations for topical administration of substances having antiandrogenic activity
US8475832B2 (en) * 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59227851A (ja) * 1983-06-09 1984-12-21 Sankyo Co Ltd レニン阻害作用を有するペプチド類
EP0181110A3 (en) * 1984-10-22 1988-05-11 Kissei Pharmaceutical Co. Ltd. Histidine derivatives as renin inhibitors
SU1676454A3 (ru) * 1984-11-30 1991-09-07 Санкио Компани Лимитед (Фирма) Способ получени пептидов или их фармацевтически приемлемых солей
DK34086A (da) * 1985-01-23 1986-07-24 Abbott Lab Peptidylaminodioler
JPS61236770A (ja) * 1985-04-15 1986-10-22 Kissei Pharmaceut Co Ltd 新規なアミノ酸誘導体
JPS6256458A (ja) * 1985-09-04 1987-03-12 Kissei Pharmaceut Co Ltd 新規なアミノ酸誘導体
EP0258289A4 (en) * 1986-01-16 1991-01-02 Joseph Dellaria Peptide analogs
IL81234A (en) * 1986-01-16 1992-09-06 Abbott Lab Peptidylaminodiols,process for their preparation and pharmaceutical compositions comprising them
US5032577A (en) * 1986-12-31 1991-07-16 Abbott Laboratories Peptidylaminodiols
US4921855A (en) * 1987-06-22 1990-05-01 Fujisawa Pharmaceutical Co., Ltd. New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same
IL87614A0 (en) * 1987-09-16 1989-01-31 Abbott Lab Peptidylheterocycles
DK523288A (da) * 1987-10-06 1989-04-07 Hoffmann La Roche Aminosyrederivater
US4902706A (en) * 1988-07-01 1990-02-20 G. D. Searle & Co. Aminoalkylaminocarbonyl aminodiol amino acid derivatives as antihypertensive agents
IE902446A1 (en) * 1989-07-26 1991-02-13 Abbott Lab Peptidyl aminodiol renin inhibitors
IE902944A1 (en) * 1989-09-05 1991-03-13 Abbott Lab Peptidyl difluorodiol renin inhibitors
EP0427939A3 (en) * 1989-10-11 1991-11-06 American Cyanamid Company Renin inhibitors
DE3937640A1 (de) * 1989-11-11 1991-05-16 Huels Chemische Werke Ag Zirkondioxidpulver, verfahren zu seiner herstellung, seine verwendung und aus ihm hergestellte sinterkoerper
US4978421A (en) * 1989-11-13 1990-12-18 International Business Machines Corporation Monolithic silicon membrane device fabrication process
TW209870B (es) * 1990-01-18 1993-07-21 Pfizer
IE68045B1 (en) * 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
US5258362A (en) * 1991-06-11 1993-11-02 Abbott Laboratories Renin inhibiting compounds
US5212185A (en) * 1992-08-14 1993-05-18 G. D. Searle & Co. Piperidinyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension

Also Published As

Publication number Publication date
US5409925A (en) 1995-04-25
EP0655062A1 (en) 1995-05-31
US5411953A (en) 1995-05-02
GR3025521T3 (en) 1998-02-27
US5422349A (en) 1995-06-06
JPH08500119A (ja) 1996-01-09
US5411950A (en) 1995-05-02
US5413998A (en) 1995-05-09
US5411954A (en) 1995-05-02
AU687753B2 (en) 1998-03-05
DE69314497T2 (de) 1998-03-05
US5409921A (en) 1995-04-25
US5409924A (en) 1995-04-25
DK0655062T3 (da) 1998-05-18
US5409945A (en) 1995-04-25
US5411961A (en) 1995-05-02
DE69314497D1 (de) 1997-11-13
EP0655062B1 (en) 1997-10-08
US5411975A (en) 1995-05-02
US5416084A (en) 1995-05-16
ATE159014T1 (de) 1997-10-15
US5411959A (en) 1995-05-02
US5409913A (en) 1995-04-25
US5409922A (en) 1995-04-25
AU5003893A (en) 1994-03-15
CA2136842A1 (en) 1994-03-03
WO1994004518A1 (en) 1994-03-03

Similar Documents

Publication Publication Date Title
ES2107192T3 (es) Compuestos de alquilamino etinil alanina amino diol morfolino/tiomorfolino-terminados utiles como inhibidores de renina.
DK0527922T3 (da) Alkoxysubstituerede dihydrobenzopyran-2-carboxylsyrer og derivater deraf
NO970512L (no) Nye heteroaryl-oksazolidinoner
DK1021456T3 (da) Makrocykliske derivater af erythromysin A og B med 13-leddet ring
MC2326A1 (fr) Antagonistes d'un nonapeptide de la bombesine
RU94045881A (ru) Производные пептидов, способ получения, фармацевтическая композиция, способ лечения
ES2141148T3 (es) N-(dihidroxi-alquil)-etinil-alaninamidas terminadas en piperidinilo para el tratamiento de la hipertension.
ES2095749T3 (es) Compuestos de alquilamino etinil alanina amino diol imidazolil/bencimidazolil-terminados utiles para el tratamiento de la hipertension.
HUP9902465A1 (hu) Új amidínium-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
IE42154L (en) Substituted phenyl ketones
DK0655058T3 (da) Pyridinyl/quinolinyl-terminerede alkylamino-ethynyl-alanin-aminodiol-forbindelser til behandling af hypertension
DK0655063T3 (da) Ethynyl-alanin-aminodiolforbindelser med piperazinyl-endegruppe eller piperazinylamino-endegruppe til behandling af hyperte
ES465927A1 (es) Un procedimiento para la produccion de compuestos tricicli- cos
DK0431520T3 (da) Heterocycliske acylaminodiol-beta-aminosyrederivater
ES2052535T3 (es) Sintesis de amino-alquil-amidas de peptidos o hidrazidas de peptidos mediante un metodo en fase solida.
HUP0303137A2 (hu) Kettős hatású antioxidáns és antiaritmiás szerek
DE69104364D1 (de) Verfahren zur herstellung von streptograminderivaten.
FI905992A0 (fi) Menetelmä metyleeni-pristinamysiini-IA- tai metyleeni-virginiamysiinijohdannaisten valmistamiseksi
ES8107249A1 (es) Un procedimiento para la preparacion de derivados de 2-epi- fortimicina.
RU2000130705A (ru) Производные индола, лекарственное средство их содержащее, способ их получения (варианты) и применение в качестве ингибитора тирозинкиназы (варианты), применение для лечения опухолевых и других заболеваний (варианты)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 655062

Country of ref document: ES